March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Incidence And Risk Factors Of Submacular Hemorrhage After Intravitreal Ranibizumab Injection For Neovascular Age Related Macular Degeneration: The Results From KORIA Study Group
Author Affiliations & Notes
  • So Young Han
    Ophthalmology, Kangbuk Samsung Hospital, Seoul, Republic of Korea
  • Sang Woong Moon
    Ophthalmology, Kyung Hee University School of Medicine, Seoul, Republic of Korea
  • Jaeryung Oh
    Ophthalmology, Korea University College of Medicine, Seoul, Republic of Korea
  • Hee Yoon Cho
    Ophthalmology, Hanyang University College of Medicine, Seoul, Republic of Korea
  • Hyeong Gon Yu
    Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
  • Su Jeong Song
    Ophthalmology, Kangbuk Samsung Hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  So Young Han, None; Sang Woong Moon, None; Jaeryung Oh, None; Hee Yoon Cho, None; Hyeong Gon Yu, None; Su Jeong Song, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3809. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      So Young Han, Sang Woong Moon, Jaeryung Oh, Hee Yoon Cho, Hyeong Gon Yu, Su Jeong Song; Incidence And Risk Factors Of Submacular Hemorrhage After Intravitreal Ranibizumab Injection For Neovascular Age Related Macular Degeneration: The Results From KORIA Study Group. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3809.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To analyze the incidence and risk factors for development or increase of macular hemorrhage after intravitreal ranibizumab injection for neovascular AMD.

 
Methods:
 

Retrospective chart review of 220 patients (220 eyes) from 5 hospitals who received intravitreal ranibizumab injection for neovascular AMD from 1 June 2009 to 30 June 2010. Systemic conditions (age, gender, presence of diabetes, hypertension, cardiovascular disease, smoking, use of anticoagulation agent) and total injection number, presence of hemorrhage at initial exam, angiographic type of choroidal neovascular membrane (CNV) were evaluated.

 
Results:
 

The incidence of development or increase of macular hemorrhage including vitreous hemorrhage was 8% (18/220). And risk factor of macular hemorrhage was presence of diabetes. (OR: 2.16, CI: 1.07-8.13). When patients had both diabetes and hypertension, the risk of macular hemorrhage after injection was increased to 4.8 folds. (OR:4.84, CI: 1.24-18.85)

 
Conclusions:
 

The systemic condition of patients was important risk factor of development or increase of macular hemorrhage after intravitreal ranibizumab injection for neovascular AMD. More consideration on status of diabetes and hypertension of patients who receives ranibizumab for neovascular AMD should be made.

 
Keywords: age-related macular degeneration • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×